scholarly journals Outcomes of excessive alcohol drinkers without baseline evidence of chronic liver disease after 15 years follow-up: Heavy burden of cancer and liver disease mortality

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0252218
Author(s):  
Sónia Bernardo ◽  
Ricardo Crespo ◽  
Sofia Saraiva ◽  
Rui Barata ◽  
Sara Gonçalves ◽  
...  
Keyword(s):  
Liver Disease ◽  
Alcohol Consumption ◽  
Chronic Liver Disease ◽  
Alcohol Intake ◽  
Chronic Liver ◽  
Portuguese Population ◽  
Heavy Drinkers ◽  
Heavy Burden

Background Most long-term heavy drinkers do not have clinically evident chronic liver disease (CLD). However, at any time-point, their risk of developing CLD remains unknown. We aimed to evaluate the long-term outcomes of a group of heavy drinkers, without evidence of CLD at baseline. Methods A cohort of 123 long-term heavy drinkers without CLD were prospectively recruited in 2002 and retrospectively followed until 2018. Results At baseline (2002), median alcohol consumption was 271±203g/day during 21.5±20 years, 65% being abstinent during the previous 1.75±5 months. Patients were followed for 14±3 years. During follow-up, 53% reported any alcohol intake. Alcohol consumption during follow-up associated weakly with either 1- or 6-months previous abstinence at baseline. Until 2018, progression to CLD occurred in 6%, associating with years of alcohol intake during follow-up (OR 1.15 [1.01–1.31]) and baseline alkaline-phosphatase (OR 1.05 [1.01–1.10]). During follow-up, being abstinent for at least 1 year positively associated with CLD-free survival. 27% died (55% of cancer–mostly oropharyngeal cancer, 27% of cardiovascular disease, and 9% of liver disease), with a mean age of 71 years [69–74] (10 years less than the expected in the Portuguese population). Achieving abstinence for at least 1 year positively associated with overall survival, while smoking, and hepatic steatosis at baseline associated negatively. Conclusion Long-term heavy drinkers seemed to have a decreased life expectancy compared with the overall Portuguese population. Cancer was the main cause of death. Our results suggest that progression to CLD depends mostly on continued alcohol intake. Alcohol abstinence, even if temporary, seems to decrease the risks of CLD and mortality.

Innovative strategies for reducing the burden of chronic liver disease

2020 ◽  
Vol 29 (Sup17) ◽  
pp. S4-S9
Author(s):  
Lynda Greenslade
Keyword(s):  
Health Economic ◽  
Liver Disease ◽  
Hepatic Encephalopathy ◽  
Alcohol Consumption ◽  
Disease Prevention ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Innovative Strategies ◽  
The Uk

Alcohol consumption is increasing in the UK, bringing an increased incidence of cirrhosis, which in turn can lead to hepatic encephalopathy. This complication of cirrhosis can be devastating for patients and their families, and incurs a large health economic burden to the NHS. Cirrhosis is, of course, preventable. As disease prevention is at the heart of the NHS Long Term Plan, it can be used as the basis of a 10-year plan to avoid the complications of chronic liver disease

Long-Term Follow-Up of Serum N-Terminal Propeptide of Collagen Type III Levels in Patients with Chronic Liver Disease

Hepatology ◽  
1984 ◽  
Vol 4 (5) ◽  
pp. 835-838 ◽  
Author(s):  
Kurt Weigand ◽  
Pierre-Yves Zaugg ◽  
Alain Frei ◽  
Arthur Zimmermann
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Collagen Type ◽  
Chronic Liver ◽  
Collagen Type Iii ◽  
Type Iii ◽  
Long Term Follow Up

scholarly journals Positive rate of C-100 antibody and changes of long term follow up cases of chronic liver disease.

Kanzo ◽  
1991 ◽  
Vol 32 (7) ◽  
pp. 683-687 ◽  
Author(s):  
Mariko KOBAYASHI ◽  
Hiromitsu KUMADA ◽  
Yasuji ARASE ◽  
Kazuaki CHAYAMA ◽  
Satoshi SAITOU ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Positive Rate ◽  
Long Term Follow Up

Long-term follow-up of hepatitis A vaccination in patients with chronic liver disease

2000 ◽  
Vol 118 (4) ◽  
pp. A1462
Author(s):  
Shou-Dong Lee ◽  
May-Ing Yu ◽  
Cho-Yu Chan ◽  
Yuan-Jen Wang ◽  
Full-Young Chang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Chronic Liver ◽  
Long Term Follow Up

scholarly journals Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases

BMC Medicine ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Karim Hamesch ◽  
Nurdan Guldiken ◽  
Mahmoud Aly ◽  
Norbert Hüser ◽  
Daniel Hartmann ◽  
...  
Keyword(s):  
Portal Hypertension ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Alcoholic Cirrhosis ◽  
Chronic Liver ◽  
Decompensated Cirrhosis ◽  
Ductular Reaction ◽  
Risk Of Death

Abstract Background Keratins (Ks) represent tissue-specific proteins. K18 is produced in hepatocytes while K19, the most widely used ductular reaction (DR) marker, is found in cholangiocytes and hepatic progenitor cells. K18-based serum fragments are commonly used liver disease predictors, while K19-based serum fragments detected through CYFRA21-1 are established tumor but not liver disease markers yet. Since DR reflects the severity of the underlying liver disease, we systematically evaluated the usefulness of CYFRA21-1 in different liver disease severities and etiologies. Methods Hepatic expression of ductular keratins (K7/K19/K23) was analyzed in 57 patients with chronic liver disease (cohort i). Serum CYFRA21-1 levels were measured in 333 Austrians with advanced chronic liver disease (ACLD) of various etiologies undergoing hepatic venous pressure gradient (HVPG) measurement (cohort ii), 231 French patients with alcoholic cirrhosis (cohort iii), and 280 hospitalized Germans with decompensated cirrhosis of various etiologies (cohort iv). Results (i) Hepatic K19 levels were comparable among F0–F3 fibrosis stages, but increased in cirrhosis. Hepatic K19 mRNA strongly correlated with the levels of other DR-specific keratins. (ii) In ACLD, increased serum CYFRA21-1 associated with the presence of clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg) (OR = 5.87 [2.95–11.68]) and mortality (HR = 3.02 [1.78–5.13]; median follow-up 22 months). (iii) In alcoholic cirrhosis, elevated serum CYFRA21-1 indicated increased risk of death/liver transplantation (HR = 2.59 [1.64–4.09]) and of HCC (HR = 1.74 [1.02–2.96]) over the long term (median follow-up 73 months). (iv) In decompensated cirrhosis, higher serum CYFRA21-1 predicted 90-day mortality (HR = 2.97 [1.92–4.60]) with a moderate accuracy (AUROC 0.64), independently from established prognostic scores. Conclusions Hepatic K19 mRNA and serum CYFRA21-1 levels rise in cirrhosis. Increased CYFRA21-1 levels associate with the presence of CSPH and reliably indicate mortality in the short and long term independently of conventional liver biochemistry markers or scoring systems. Hence, the widely available serum CYFRA21-1 constitutes a novel, DR-related marker with prognostic implications in patients with different settings of advanced liver disease.

Long-term follow-up of hepatitis A vaccination in patients with chronic liver disease

2000 ◽  
Vol 95 (9) ◽  
pp. 2516-2516
Author(s):  
Shou-Dong Lee ◽  
May-Ing Yu ◽  
Cho-Yu Chan ◽  
Yuan-Jen Wang ◽  
Full-Young Chang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Chronic Liver ◽  
Long Term Follow Up

Hypermanganesemia in Long-Term Intravenous Nutrition and Chronic Liver Disease

1999 ◽  
Vol 23 (6) ◽  
pp. 350-355 ◽  
Author(s):  
Catherine A. Wardle ◽  
Alastair Forbes ◽  
Norman B. Roberts ◽  
A.V. Jawhari ◽  
Alan Shenkin
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Intravenous Nutrition

scholarly journals Chronic Hepatitis C Virus Infection After Treatment for Pediatric Malignancy

Blood ◽  
1997 ◽  
Vol 90 (3) ◽  
pp. 1315-1320 ◽  
Author(s):  
Simone Cesaro ◽  
Maria Grazia Petris ◽  
Flavio Rossetti ◽  
Riccardo Cusinato ◽  
Corrado Pipan ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Infection ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Hcv Infection ◽  
Pediatric Malignancy ◽  
Infection Markers

Abstract Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.

Sign in / Sign up

Export Citation Format

Share Document